Article
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Journal of biomedicine & biotechnology - 1 Jan 2011
Kosaka Takayuki, Yamaki Ei, Mogi Akira, Kuwano Hiroyuki
Abstract excerpt
Gefitinib and erlotinib, which are epidermal growth factor receptor- (EGFR-) specific tyrosine kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non-small-cell lung cancer (NSCLC). Currently, the search for EGFR gene mutations is becoming essential for the treatment of NSCLC since these have been identified as predictive factors for drug sensitivity. On the other hand, in almost all...
Topics
- Carcinoma, Non-Small-Cell Lung
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib
- Gene Expression Regulation, Neoplastic
- Hepatocyte Growth Factor
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins c-met
- Quinazolines
- Receptors, Growth Factor